Adverse Event, Chronic Graft-versus-host-disease, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Response Rate
Conditions
Keywords
acalabrutinib, Chronic Lymphocytic Leukaemia, allogeneic haematopetic cell transplantation, Chronic Graft-versus-host-disease, Minimal Residual Disease, reduced intensity conditioning, Mantle Cell Disease
Brief summary
In this phase II multicenter trial we plan to use acalabrutinib before and after allogeneic hematopoietic stem cell transplantation (alloSCT) with reduced intensity conditioning (RIC) in patients with refractory/relapsed MCL and CLL with poor prognostic factors. Acalabrutinib will be used before alloSCT with the intention to reduce tumor burden and after transplant to augment disease control.
Detailed description
In this phase II multicenter trial we plan to use acalabrutinib before and after allogeneic hematopoietic stem cell transplantation (alloSCT) with reduced intensity conditioning (RIC) in patients with refractory/relapsed MCL and CLL with poor prognostic factors. Acalabrutinib will be used before alloSCT with the intention to reduce tumor burden and after transplant to augment disease control. Since chronic GvHD is mediated by activated B lymphocytes, we also speculate that the drug as a BTK inhibitor may reduce the severity and incidence of chronic graft-versus-host disease (GvHD) after alloSCT, as it was shown for ibrutinib. Best response to therapy and safety issues will be the primary target of this small trial (25 transplanted pts).TEAE and SAE of acalabrutinib in patients after alloSCT that was not previously assessed. We hypothesize that this treatment will improve the efficacy of the alloSCT - this issue will be addressed by serial minimal residual disease (MRD) evaluation in peripheral blood and bone marrow. This treatment strategy could significantly improve the outcome of poor prognosis MCL and CLL patients.
Interventions
DRUGAcalabrutinib 2x100 MG Oral Capsule + alloSCT
Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.
Sponsors
AstraZeneca
Polish Lymphoma Research Group
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Multicentre, national
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Men and women ≥ 18 years of age. 2. Relapsing / refractory BTK-inhibitors naïve CLL patients meeting IWCCL criteria for requiring treatment: 1. after 1-4 therapy lines if del 17 or p53 mutation in \>10% of analyzed CLL cells (PB or BM) or 2. after 2-4 therapy lines if high risk CLL (refractory or less than 24 months response to the last immunochemotherapy) or Confidential Page 15 of 82 Study Protocol v. 1.5 dated 06.07.2018 3. Relapsing / refractory BTK-inhibitors naïve MCL patients with measurable disease or bone marrow involvement revealed in trephine biopsy or 4. Patients fulfilling criteria 2 or 3, when ibrutinib therapy was initiated, responding to therapy 5. Patient qualified for allo SCT procedure by the transplant center participating in the trial with identified sibling donor or initiated Poltransplant search for matched unrelated donor. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 7. Woman of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and for 2 days after the last dose of acalabrutinib and for 6 months after the transplant procedure if performed. Males who are sexually active must use highly effective methods of contraception during treatment and for 6 months after the transplant procedure if performed. 8. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty. 9. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information
Exclusion criteria
1. Patients failing 5 or more previous therapy lines 2. Prior malignancy (or any other malignancy that requires active treatment), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 5 years 3. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or Confidential Page 16 of 82 Study Protocol v. 1.5 dated 06.07.2018 any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification (NYHA). Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study. 4. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass. 5. Impaired hepatic function (as indicated by any of the following): 1. Serum total bilirubin \> 2.5 x upper limit of normal (ULN) 2. Alanine amino transferase and/or aspartate amino transferase \> 2.5 x ULN 3. Alkaline phosphatase \> 2.5 x ULN 6. Impaired renal function: serum creatinine \> 2.5 x ULN 7. Other concurrent serious diseases that increase Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) \> 4 8. Central nervous system involvement with CLL 9. Known history of drug-specific hypersensitivity or anaphylaxis to study drug (including active product or excipient components). 10. Active bleeding, history of bleeding diathesis (eg, hemophilia or von Willebrand disease). 11. Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura). 12. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening. 13. Requiring or receiving a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer (see appendix 3 for a complete list) Confidential Page 17 of 82 Study Protocol v. 1.5 dated 06.07.2018 14. Requiring or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days of first dose of study drug. 15. Requiring proton pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study. 16. Prothrombin time/INR or aPTT (in the absence of Lupus anticoagulant) \> 2x ULN. 17. History of significant cerebrovascular disease or event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug. 18. Major surgical procedure within 30 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug. 19. Known history of infection with HIV or any active uncontrolled systemic infection 20. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded. 21. ANC \< 500/μl, Platelets \< 20 000/μl, and hemoglobin \< 8 g/dl 22. Breastfeeding or pregnant. 23. Concurrent participation in another therapeutic clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate | through study completion on average 27 months | Nr of patients with partial and complete response (PR and CR), |
| Response to therapy Minimum residual disease CR (MRD CR) rate | through study completion on average 27 months | Nr of patients with minimum residual disease CR (MRD CR) assessed by flow cytometry in peripheral blood (PB) and bone marrow (BM) |
| Adverse event/serious adverse event incidence | acalabrutinib completion or discontinuation plus 30 days of the last acalabrutinib dose | Incidence of adverse events per system |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Non-relapse mortality | through study completion on average 27 months | Nr of patients who died being in continuous remission |
| Relapse incidence | through study completion on average 27 months | Nr of patients with return of a disease or the signs and symptoms of a disease after a period of improvement |
| Progression free survival | through study completion on average 27 months | Nr of days from assignment in a clinical trial to disease progression or death from any cause |
Countries
Poland
Outcome results
None listed